Dr. Robert Hollingsworth is the Vice-President and Chief Scientific Officer for Cancer Vaccines and Immunotherapeutics at Pfizer. He oversees research and development from target discovery through clinical proof-of-concept. He also is an Adjunct Assistant Professor of Oncology at Johns Hopkins School of Medicine, and has led numerous industry-academic alliances. Prior to joining Pfizer, Dr. Hollingsworth was Senior Director of Oncology Research at MedImmune where he led work to advance several cancer drugs into the clinic, including immuno-oncology antibodies and antibody-drug conjugates. He also previously served as a Director and Head of the Oncology Therapeutic Area Team at GlaxoSmithKline, where he conducted cancer genetics research and contributed the development of several small molecule cancer medicines, including Tykerb. He studied biology and physics as an undergraduate at the University of California, Berkeley, and received a Ph.D. in biochemistry, biophysics, and genetics from the University of Colorado. His post-doctoral studies elucidated the connections between cell cycle control and the function of tumor suppressor proteins.
Dr. Hollingsworth’s scientific expertise includes immuno-oncology, cancer vaccines, oncolytic viruses, antibodies, and small molecule cancer drugs. He has been an invited speaker at numerous conferences, and received several prestigious awards including an American Cancer Society Fellowship, an NIH Postdoctoral Fellowship, several pharma excellence awards, and an ARCS award for the top graduate scholar in Colorado. Dr. Hollingsworth has published many papers in top journals, including Nature, Science, and Cancer Research, and co-authored a seminal paper on the contribution of microenvironment factors to tumorigenesis that was named one of the top “milestones in cancer research” by Nature.